4.7 Article

Charcot-Marie-Tooth disease misdiagnosed as chronic inflammatory demyelinating polyradiculoneuropathy: An international multicentric retrospective study

Journal

EUROPEAN JOURNAL OF NEUROLOGY
Volume 28, Issue 9, Pages 2846-2854

Publisher

WILEY
DOI: 10.1111/ene.14950

Keywords

Charcot-Marie-Tooth disease; chronic inflammatory demyelinating polyneuropathy

Ask authors/readers for more resources

This study found that 35 out of 1104 patients initially diagnosed with CIDP actually had CMT. The cost of treating these misdiagnosed patients was significantly higher than the cost of performing CMT genetic analysis in the larger patient group, indicating the importance of utilizing CMT genetic investigations before diagnosing CIDP.
Background and purpose Charcot-Marie-Tooth (CMT) disease, an untreatable hereditary polyneuropathy, may mimic chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), a treatable neuropathy. Methods In this retrospective study, we analyzed the characteristics of CMT patients misdiagnosed as CIDP at 16 university hospitals in three countries, compared these patients with a reference group of CIDP patients, and estimated the cost of misdiagnosis. Results Among 1104 CIDP cases, we identified 35 CMT patients misdiagnosed as CIDP (3.2%). All were initially diagnosed with definite or probable CIDP (European Federation of Neurological Societies/Peripheral Nerve Society criteria), and mutations in PMP22, MPZ, and 10 other CMT genes were found in 34%, 31%, and 35% of cases, respectively. In comparison with a reference group of 35 CIDP patients, CMT patients were younger (median age at disease onset = 39 vs. 56 years) and more frequently had motor weakness at disease onset (80% vs. 29%), hearing loss (14% vs. 0%), normal brachial plexus imaging (70% vs. 40%), lower cerebrospinal fluid protein content (median = 0.5 vs. 0.8 g/L), and lower treatment response (20% vs. 69%). Treatment cost in these 35 misdiagnosed patients was estimated at 4.6 million euros (Meuro), whereas the cost of CMT genetic analysis in 1104 patients was estimated at 2.7 Meuro. Conclusions In this study, 35 of 1104 (3.2%) patients initially diagnosed with CIDP had CMT. Importantly, the cost of treating these 35 misdiagnosed patients was significantly higher than the cost of performing CMT genetic analysis in 1104 patients (4.6 Meuro vs. 2.7 Meuro), suggesting that CMT genetic investigations should be more widely used before diagnosing CIDP.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available